SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.

ETFs Shijiazhuang Yiling Pharmaceutical Co., Ltd.

002603

CNE1000015S0

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 2025-06-20			5-day change	1st Jan Change
13.91 ^CNY	-0.07%		-4.20%	-13.12%

04-28	Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
01-22	Yiling Pharmaceutical's Unit Gets Registration Certificate for Qifangbitong Tablets	MT

ETFs positioned on Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Name	Weight	AuM	1st Jan change
KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX UCITS ETF - USD	0.9%	0 M€	-19.71%	-
GOLDMAN SACHS ACTIVEBETA EMERGING MARKETS EQUITY UCITS ETF - ACC - USD	0.07%	8 M€	+13.20%	-
LEVERAGE SHARES -3X SHORT CHINA ETP SECURITIES - USD	0.02%	0 M€	0.00%	-
LEADERSHARES EQUITY SKEW ETF - USD	0.01%	89 M€	-4.88%	-
DAY HAGAN/NED DAVIS RESEARCH SMART SECTOR INTERNATIONAL ETF - USD	0%	32 M€	+10.95%	-
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS - VANGUARD FTSE ALL-WORLD EX-US ETF	0%	33,076 M€	+8.84%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR	0%	53 M€	-3.80%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	0%	619 M€	-3.30%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - DISTRIBUTING - EUR	0%	61 M€	-2.80%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - ACC - EUR	0%	467 M€	-1.66%	-
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF - DISTRIBUTING - EUR	0%	28 M€	-1.85%	-
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF ACC - EUR	0%	139 M€	-0.39%	-
DEMOCRACY INTERNATIONAL FUND ETF - USD	0%	9 M€	+12.50%	-
NOMURA NEXT FUNDS EMERGING MARKET EQUITY MSCI-EM (UNHEDGED) ETF - JPY	0%	17 M€	+2.33%	-
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF ACC - EUR	0%	68 M€	+0.59%	-
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF - DISTRIBUTING - EUR	0%	10 M€	-1.06%	-

Shijiazhuang Yiling Pharmaceutical Co Ltd is a China-based company principally engaged in research, development, production and sales of patented innovative traditional Chinese medicine. The Company operates three business sectors. The Proprietary Chinese Medicine sector is mainly engaged in multi-channel research and development of compound Chinese medicines, component Chinese medicines and single Chinese medicines. The Chemopharmaceutical sector mainly establishes chemopharmaceutical research and development platform, international standard production platform and network of overseas sales partners. The Health Industry sector has developed and launched a series of health products, including products of benefiting heart and brain, anti-aging and immunity, anti-fatigue and anti-joint, sleep and mood and Lianhua respiratory health. The Company also provides dietary supplements, healthy food and drink, disinfection products and personal protective equipment.

Employees

11,708

Sector

Pharmaceuticals

Calendar

08-27 - Q2 2025 Earnings Release (Projected)

More about the company